Good morning, CIOs. Sooner or later it happens to every company during its generative AI journey. One day, everyone's empowered to experiment. The next, the pros take over.
Jim Swanson, chief information officer at Johnson & Johnson, talked with the Journal's Isabelle Bousquette about the time the healthcare conglomerate shifted its generative AI strategy away from broad experimentation to a more focused approach.
“That was a pivot we made after about a year of learning,” Swanson said. “Now we’ve moved from the thousand flowers to a really prioritized focus on GenAI.”
That “thousand flowers” approach involved a number of use-case ideas germinating from across the company. At one point, employees were pursuing nearly 900 individual use cases, he said.
Now J&J is drilling down into high-impact generative AI use cases in areas such as drug discovery and supply chains, as well as an internal chatbot to answer questions on company policy.
“We’re prioritizing, we’re scaling, we’re looking at the things that make the most sense,” he said. “That was part of the maturation process we went through.” Read the story.
|